Pharmacokinetic profile of bitopertin, a selective GlyT1 inhibitor, in the rat

Bitopertin, a selective glycine transporter 1 (GlyT(1)) inhibitor, has been extensively studied for the treatment of schizophrenia, with known safety and tolerability profiles in the clinic. Whereas several rodent experiments have been reported, the pharmacokinetic (PK) profile of bitopertin in rodents has not been extensively reported, as only two studies disclosed limited PK parameters in male rats after oral administration. Here, we determined the PK profile of bitopertin in female Sprague-Dawley rats. Blood samples were taken serially, before and after sub-cutaneous (0.03, 0.1, 0.3, 1, and 3 mg/kg) or intra-venous (0.1 mg/kg) administration. Plasma levels were determined by high-performance liquid chromatography coupled with heat-assisted electrospray ionisation tandem mass spectrometry (HPLC-HESI MS/MS). Subsequently, PK parameters were calculated using non-compartmental analysis, including area under the curve (AUC), time (T-max) to maximal plasma concentration (C-max), clearance (CL), volume of distribution (V-z), as well as half-life (T-1/2). Following sub-cutaneous injection, bitopertin exhibited dose-dependent AUC(0-infinity) (439.6-34,018.9 ng/mL) and T-max (3.7-24.0 h), a very long terminal T-1/2 (35.06-110.32 h) and low CL (0.07-0.13 L/h/kg), suggesting that bitopertin is slowly absorbed and eliminated in the rat. The observed relationship between dose and the extent of drug exposure (AUC) was linear. Following administration of all sub-cutaneous doses, measured bitopertin plasma levels were comparable to levels achieved with doses already administered in the clinic. We hope that our results will be useful in the design of pre-clinical experiments in which this drug will eventually be administered sub-cutaneously.

Automated summary

This study determined the pharmacokinetic profile of bitopertin in female Sprague-Dawley rats, finding dose-dependent AUC and T-max that showed a linear relationship and comparable plasma levels to those achieved in the clinic. These results will be useful in designing pre-clinical experiments for the sub-cutaneous administration of this drug in the future.